Instructions to authors
Publication and Research Ethics
Disclosure of potential conflicts of interest
Availability of data and materials
Publishing agreements and charges
How we publish
Antibody Therapeutics is a peer reviewed fully open access journal publishing 4 continuous publication issues per year online. All papers published in the Journal are made freely available online under open access publishing agreements, with applicable charges. Please refer to the open access section below.
Once a paper is accepted and the publishing agreement is signed, the Journal will publish the Accepted Manuscript version of the paper (before copyediting and review of the final proof) within one week on the Advance Articles page. The Accepted Manuscript will be removed from Advance Articles when the Version of Record of the paper (after copyediting and proof review process) is published in the currently open issue. Substantial changes to the published Accepted Manuscript may require a correction notice.
Peer Review
Antibody Therapeutics conducts rigorous and constructive single-anonymized peer review, meaning that the identity of the authors is known to the editors and to the reviewers, but that the reviewers’ identities are known only to the editors and are hidden from the authors.
All submissions to the journal are initially reviewed by one of the Editors. At this stage manuscripts may be rejected without peer review if it is felt that they are not of high enough priority or not relevant to the journal. This fast rejection process means that authors are given a quick decision and do not need to wait for the review process.
Manuscripts that pass the editorial review are sent out for peer review, to at least two independent reviewers. Based on the feedback from these reviewers and the Editors' judgment a decision is given on the manuscript.
If a paper is not acceptable in its present form, we will pass on suggestions for revisions to the author.
In the case of manuscripts in which one of the authors is a member of the editorial staff of the journal, that editor will be blinded from reviewing or making decisions on the manuscript, and this will be acknowledged in the conflict-of-interest statement of the published paper.
For information on the journal's review process or a manuscript's progress, please contact the editorial office.
Appeals and complaints
Authors may appeal an editorial decision. To do so, please contact the editorial office, providing as much specific detail as possible about why the original decision should be reconsidered. Every appeal will receive a response within a reasonable timeframe. Please do not resubmit your manuscript in the interim.
To register a complaint regarding non-editorial decisions, the Journal’s policies and procedures, editors, or staff, please contact us. Complaints will be taken seriously and will be carried forward following COPE guidelines and processes and/or sanctions will be enacted if deemed appropriate.
Publication and research ethics
Authors should observe high standards with respect to publication ethics as set out by the Committee on Publication Ethics (COPE). Falsification or fabrication of data, plagiarism, including duplicate publication of the authors' own work without proper citation, and misappropriation of the work are all unacceptable practices. Any cases of ethical misconduct are treated very seriously and will be dealt with in accordance with the COPE guidelines.
Authorship
Authorship is confined to those who have made a significant contribution to the design and execution of the work described. Any contributors whose participation does not meet the criteria for authorship should be acknowledged but not listed as an author. For a detailed definition of authorship, please see the International Committee of Medical Journal Editors (ICMJE) definitions of authors and contributors.
The Journal does not allow ghost authorship, where an unnamed author prepares the article with no credit, or guest/gift authorship, where an author who made little or no contribution is listed as an author. The Journal follows Committee on Publication Ethics (COPE) guidance on investigating and resolving these cases. For more information, please see the OUP Publication Ethics page.
Natural language processing tools driven by artificial intelligence (AI) do not qualify as authors, and the Journal will screen for them in author lists. The use of AI (for example, to help generate content, write code, or process data) should be disclosed both in cover letters to editors and in the Methods or Acknowledgements section of manuscripts. Please see the COPE position statement on Authorship and AI for more details.
After manuscript submission, no authorship changes (including the authorship list, author order, and who is designated as the corresponding author) should be made without the approval of the editor. All co-authors must agree on the change(s), and neither the Journal nor the publisher mediates such disputes. If individuals cannot agree on the authorship of a submitted manuscript, contact the editorial office. The dispute must be resolved among the individuals and their institution(s) before the manuscript can be accepted for publication. If an authorship dispute or change arises after a paper is accepted, contact OUP’s Author Support team. COPE provides guidance for authors on resolving authorship disputes.
If you intend to use Read and Publish funding to publish your manuscript under an open access license, note that changing the corresponding author to access those funds is not permissible. For more information on Read and Publish funding, see the Open access charges section.
ORCiD
Submitting authors are required to provide an ORCID iD (Open Researcher and Contributor ID) at submission.
If you do not already have an ORCID iD, you can register for free via the ORCID website.
As ORCID identifiers are collected, they are included in papers and displayed online, both in the HTML and PDF versions of the publication, in compliance with recommended practice issued by ORCID.
ORCID functionality online allows users to link to the ORCID website to view an author’s profile and list of publications. ORCID iDs are displayed on web pages and are sent downstream to third parties in data feeds, where supported.
If you have registered with ORCID, you can associate your ORCID iD with your submission system account by going to your account details, entering your ORCID iD, and validating your details. Learn more about ORCID and how to link it to your account.
CRediT
The Journal uses the contributor roles taxonomy (CRediT), which allows authors to describe the contributor roles in a standardized, transparent, and accurate way. Authors should choose from the contributor roles outlined on the CRediT website and supply this information upon submission. You may choose multiple contributor roles per author. Any other individuals who do not meet authorship criteria and made less substantive contributions should be listed in your manuscript as non-author contributors with their contributions clearly described.
Disclosure of potential conflicts of interest
Authors
The Journal requires all authors to disclose any potential conflict of interest at the point of submission. It is the responsibility of the corresponding author to ensure that conflicts of interest of all authors are declared to the Journal. Authors must do this by including a conflict-of-interest statement after the acknowledgements in your submitted manuscript. Authors with commercial or industry affiliations must disclose all relevant direct and indirect financial relationships, including but not limited to employment, consulting, investments, or stock. If there are no conflicts of interest, please list ‘None’. This is required for all article types.
A conflict of interest exists when the position, activities, or relationships of an individual, whether direct or indirect, financial or non-financial, could influence or be seen to influence the opinions or activities of the individual. For more information, refer to OUP’s definition of conflict of interest.
The Journal follows the COPE guidance for any undisclosed conflict of interest that emerges during peer review, production, or after publication.
Peer reviewers
Individuals that have a conflict of interest relating to a submitted manuscript should recuse themselves and will not be assigned to oversee, handle, or peer review the manuscript.
If during peer review an editor, reviewer, or author becomes aware of a conflict of interest that was not previously known or disclosed they must inform the Editor-in-Chief immediately.
Editors and editorial board members
At initial submission, the corresponding author must declare if the Editor-in-Chief, an Editor, or an Editorial Board Member of the Journal is an author of or contributor to the manuscript. Another Editor without a conflict of interest will oversee the peer review and decision-making process. If accepted, a statement will be published in the paper describing how the manuscript was handled.
Members of the editorial staff of the journal should include the following COI disclosure in their article: '[Author initial] holds the position of [Editor-in-Chief/Deputy Editor-in-Chief/Assistant Editor/Editorial Board Member] for Antibody Therapeutics and is blinded from reviewing or making decisions for the manuscript.
Previously published material
You should only submit your manuscript(s) to Antibody Therapeutics if:
- It is original work by you and your co-author(s).
- It is not under consideration, in peer review, or accepted for publication in any other publication.
- It has not been published in any other publication.
- It contains nothing abusive, defamatory, derogatory, obscene, fraudulent, or illegal.
The submitting author must disclose in their cover letter and provide copies of all related or similar preprints, dissertations, manuscripts, published papers, and reports by the same authors (i.e., those containing substantially similar content or using the same, similar, or a subset of data) that have been previously published or posted electronically or are under consideration elsewhere at the time of manuscript submission. You must also provide a concise explanation of how the submitted manuscript differs from these related manuscripts and papers. All related previously published papers should be cited as references and described in the submitted manuscript.
For previously published materials including tables and figures, please see the Reusing copyrighted materials section.
Preprints
As an author, you retain the right to make an Author’s Original Version (preprint) available through various channels and this does not prevent submission to the Journal. If accepted, the authors are required to update the status of any preprint, including adding your published paper’s DOI. For full details on allowed channels and updating your preprint, please see our Author self-archiving policy.
Reusing copyrighted material
As an author, you must obtain permission for any material used within your manuscript for which you are not the rightsholder, including quotations, tables, figures, or images. In seeking permissions for published materials, first contact the publisher rather than the author. For unpublished materials, start by contacting the creator. Copies of each grant of permission should be provided to the editorial office of the Journal. The permissions agreement must include the following:
- nonexclusive rights to reproduce the material in your paper in Antibody Therapeutics
- rights for use in print and electronic format at a minimum, and preferably for use in any form or medium
- lifetime rights to use the material
- worldwide English-language rights
It is particularly important to clear permission for use in both the print and online versions of the journal, and we are not able to accept permissions which carry a time limit because we retain journal articles as part of our online journal archive.
If you have chosen to publish under an open access license but have not obtained open access re-use permissions for third-party material contained within the manuscript, this must be stated clearly by supplying a credit line alongside the material with the following information:
- Title of content
- Author, Original publication, year of original publication, by permission of [rightsholder]
- This image/content is not covered by the terms of the Creative Commons license of this publication. For permission to reuse, please contact the rights holder.
Further guidelines on clearing permissions can downloaded as a pdf.
Our publisher, Oxford University Press, provides detailed Copyright and Permissions Guidelines, and a summary of the fundamental information.
Misconduct
Authors should observe high standards with respect to research integrity and publication ethics as set out by the Committee on Publication Ethics (COPE). Falsification or fabrication of data including inappropriate image manipulation, plagiarism, including duplicate publication of the author's own work without proper citation, and misappropriation of work are all unacceptable practices. Allegations of ethical misconduct, both directly and through social media, are treated seriously and will be investigated in accordance with the relevant COPE guidance.
If misconduct has been established beyond reasonable doubt, this may result in one or more of the following outcomes, among others:
- If a submitted manuscript is still under consideration, it may be rejected and returned to the author.
- If a paper has already been published online, depending on the nature and severity of the infraction, either a correction notice will be published and linked to the paper, or retraction of the paper will occur, following the COPE Retraction Guidelines.
- The relevant party’s institution(s) and/or other journals may be informed.
Manuscripts submitted to the Journal may be screened with plagiarism-detection software. Any manuscript may be screened, especially if there is reason to suppose that part or all the of the manuscript has been previously published.
COPE defines plagiarism as “when somebody presents the work of others (data, words or theories) as if they were their own and without proper acknowledgment.”
COPE defines redundant/overlapping publication as “when a published work (or substantial sections from a published work) is/are published more than once (in the same or another language) without adequate acknowledgment of the source/cross-referencing/justification,
or
when the same (or substantially overlapping) data is presented in more than one publication without adequate cross-referencing/justification, particularly when this is done in such a way that reviewers/readers are unlikely to realise that most or all the findings have been published before.”
COPE defines citation manipulation as “behaviours intended to inflate citation counts for personal gain, such as: excessive self-citation of an authors’ own work, excessive citation to the journal publishing the citing article, and excessive citation between journals in a coordinated manner.”
Data fabrication is defined as intentionally creating fake data or misrepresenting research results. An example includes making up data sets.
Data falsification is defined as manipulating research data with the purpose of intentionally giving a false representation. This can apply to images, research materials, equipment, or processes. Examples include cropping of gels/images to change context and omission of selected data.
If notified of a potential breach of research misconduct or publication ethics, the Journal editor and editorial office staff may inform OUP and/or the author’s institutional affiliation(s).
Ethical research
Antibody Therapeutics follows Committee on Publication Ethics (COPE) guidelines on ethical oversight. We take research integrity seriously, and all research published in the Journal must have been conducted in a fair and ethical manner. Wherever appropriate, the Journal requires that all research be done according to international and local guidelines.
Human subjects
When reporting on human subjects, you should indicate whether the procedures followed were in accordance with the ethical standards of the Helsinki Declaration, which were developed by the World Medical Association. For non-interventional studies, where ethical approval is not required or where a study has been granted an exemption by an ethics committee, this should be stated within the manuscript with a full explanation. Otherwise, manuscripts must include a statement in the Methods section that the research was performed after approval by a local ethics committee, institutional review board and/or local licensing committee, or that such approval was not required. The name of the authorizing body and any reference/permit numbers (where available) should also be stated there. Please be prepared to provide further information to the editorial office upon request.
Human subjects must give written informed consent, or if they are minors or incapacitated, such consent must be obtained from their parents or guardians. Consent forms should cover not only study participation but also the publication of the data collected. Also, any patient or provider information should be anonymized to the extent possible; names and ID numbers should not be used in the text and must be removed from any images (X-rays, photographs, etc.). Please note blanking out an individual’s eyes in a photograph is not an effective way to conceal their identity. In studies where verbal, rather than written, informed consent was obtained, this must be explained and stated within the manuscript. If informed consent is not required or where a study has been granted an exemption, this must be included in the Methods section along with the name of the authorizing body. Please be prepared to provide written consent forms signed by the participants or other appropriate documentation to the editorial office upon request.
These statements should be included under an ‘Ethics and consent’ subheading at the end of the manuscript after the acknowledgements. If consent was not required, please state ‘Not applicable’. This is required for research articles and brief reports.
Clinical trials
Clinical trials should be registered before enrollment of the first subject in accordance with the criteria outlined by the International Committee of Medical Journal Editors (ICMJE). When reporting primary or secondary analyses from a clinical trial, follow these criteria:
- Provide the trial registration number at the end of the Abstract.
- When the trial acronym is first used in the manuscript, provide the registration number and a link to the trial registration, which should be cited as a reference.
- If your data have been deposited in a public repository and/or are being used in a secondary analysis, please state at the end of the Abstract the unique, persistent data set identifier, and repository name and number.
- When submitting the manuscript, you must disclose any protocol alterations and all posting of results of the submitted work or closely related work in registries.
Where available, registration numbers should be provided not only for the trial you are reporting but also for any other trial mentioned in the manuscript. When the trial acronym is first used in the manuscript, provide the registration number and a link to the trial registration, which should be cited as a reference.
Animal subjects
Studies involving animals require approval from the relevant institutional ethics committee or institutional animal use and care committee, and the research must be conducted in accordance with applicable national and international guidelines. All such manuscripts must include a statement in the Methods section providing details of the name of the committee(s) that approved the study, as well as the permit or animal license numbers where available. Where a study has been granted an exemption, this must be stated in the Methods section along with the name of the authorizing body. Please be prepared to provide further information to the editorial office upon request.
Authors should also include an ‘Animal Research Statement’ subheading at the end of the manuscript after the acknowledgements that states all relevant disclosures. If a study does not use animals, please state ‘Not applicable’. The journal reserves the right to reject papers where the ethical aspects are, in the Editor's opinion, open to doubt. This is required for research articles and brief reports.
ARRIVE guidelines
You are encouraged to consult the ARRIVE guidelines recommended by the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3R).
Euthanasia or Anesthesia Methods
Where applicable, any euthanasia or anesthesia methods must be carried out in accordance with applicable veterinary guidelines. These methods must be described in detail in the manuscript.
Laboratory Animals
Manuscripts describing research involving laboratory-based animals must include details on housing, husbandry, and steps taken to reduce suffering. In studies where experimental animals were euthanized, details must be provided on humane endpoints. Details on the planned behavioral observations or physiological measurements used to determine the humane endpoint must be described. You are advised to consult the NC3Rs guide on Humane Endpoints and the American Veterinary Medical Association (AVMA) Guidelines for the Humane Slaughter of Animals.
Funding
All sources of research funding, including grants, direct and indirect financial support, supply of equipment, or materials (including specialist statistical or writing assistance) should be declared with article submission. You must do this by including a Funding statement after the acknowledgements in your submitted manuscript. Authors with direct or indirect commercial or industry funding must declare the funding, as well as include a description of the nature of the funder's involvement in the research design, execution, analysis, interpretation, reporting, or decision to submit it for publication. If there is no funding to declare, please list ‘None’. This is required for all manuscript types.
Availability of data and materials
Where ethically feasible, Antibody Therapeutics strongly encourages authors to make all data and software code on which the conclusions of the paper rely available to readers. Authors are required to include a Data Availability Statement in their article.
We suggest that data be presented in the main manuscript or additional supporting files, or deposited in a public repository whenever possible. Information on general repositories for all data types, and a list of recommended repositories by subject area.
Data Availability Statement
The inclusion of a Data Availability Statement is a requirement for articles published in Antibody Therapeutics. Data Availability Statements provide a standardized format for readers to understand the availability of data underlying the research results described in the article. The statement may refer to original data generated in the course of the study or to third-party data analyzed in the article. The statement should describe and provide means of access, where possible, by linking to the data or providing the required unique identifier.
The Data Availability Statement should be included in the end matter of your article under the heading ‘Data availability’. This is required for all article types.
More information and example Data Availability Statements.
Data Citation
Antibody Therapeutics supports the Force 11 Data Citation Principles and requires that all publicly available datasets be fully referenced in the reference list with an accession number or unique identifier such as a digital object identifier (DOI). Data citations should include the minimum information recommended by DataCite:
- [dataset]* Authors, Year, Title, Publisher (repository or archive name), Identifier
*The inclusion of the [dataset] tag at the beginning of the citation helps us to correctly identify and tag the citation. This tag will be removed from the citation published in the reference list.
Self-archiving
Self-archiving refers to posting a copy of your work on a publicly accessible website or repository. Under certain circumstances, you may self-archive versions of your work on your own webpages, on institutional webpages, and in other repositories. For information about the Journal's policy, and to learn which version(s) of your paper are acceptable for self-archiving, please see our Author self-archiving policy.
Publishing agreements and charges
Publishing agreement
Antibody Therapeutics is a fully open access journal, and all articles are published in the journal under an open access license immediately upon publication.
After your manuscript is accepted, you will be asked to sign a licence to publish through the Journals Licencing and Online Payments portal. The Journal is fully open access, meaning all papers in the Journal are published under an open access licence. The corresponding author will need to arrange payment of an open access charge to publish in the Journal. This charge allows all published papers to be immediately and freely available to all readers immediately upon online publication. Editorial decisions are made independent of waiver decisions and/or payment workflows.
Charges
Papers can be published under the following:
CC BY, CC BY-NC non-member rate – $2,822
Member discount – 20%
Please note that non-research content, i.e. Editorials, News & Views, Meeting Reports, and Interviews will not be subject to an APC.
Authors must pay an open access fee (APC) to publish in the journal as of November 1, 2022.
If you would like to submit to ABT but are unable to pay the APC, you may be eligible for an APC waiver. More information about this policy. For discretionary waiver requests, you may contact openaccess@oup.com before manuscript submission to request an APC waiver. Please note that not all waiver requests may be granted.
Corresponding authors based in countries and regions, that are part of the developing countries initiative are eligible for a full waiver of publishing fees in our fully open access journals. For further details, please see our APC Waiver Policy.
OUP has a growing number of Read and Publish agreements with institutions and consortia which provide funding for open access publishing. This means authors from participating institutions can publish open access, and the institution may pay the charge. Find out if your institution is participating.
To be eligible for one of OUP’s Read and Publish agreements, the corresponding author must provide their qualifying institution as their primary affiliation when they submit their manuscript. After submission, changing the corresponding author in order to access Read and Publish funding is not permissible.
Member discounts
Corresponding authors who are members of the Chinese Antibody Society are eligible for a 20% APC discount. Authors will be asked to prove eligibility for the member discount at time of manuscript submission.
Complying with funder mandates
Please note that some funders require open access publication as a condition of funding. If you are unsure whether you are required to publish open access, please do clarify any such requirements with your funder or institution before selecting your licence.
Further information on funder mandates and direct links to a range of funder policies.
Changes to published papers
The Journal will only make changes to published papers if the publication record is seriously affected by the academic accuracy of the published information. Changes to a published paper will be accompanied by a formal correction notice linking to and from the original paper.
As needed, we follow the COPE guidelines on retractions.
For more information and details of how to request changes, including for authors who wish to update their name and/or pronouns, please see OUP’s policy on changes to published papers.
Preparing your manuscript
General guidelines on preparing your manuscript for publication can be found on OUP’s Preparing and submitting your manuscript page. Specific instructions for Antibody Therapeutics can be found below.
Scope
Antibody Therapeutics will consider publication of manuscripts that deal with the broad field of antibody therapeutics and have not been published, simultaneously submitted, or already accepted for publication elsewhere. This does not preclude consideration of a complete report that follows publication of preliminary findings elsewhere.
Submission
All manuscripts are submitted and reviewed via the journal's web-based manuscript submission system. New authors should create an account prior to submitting a manuscript for consideration. Questions about submitting to the journal should be sent to the editorial office.
Article Types
Research articles:
Report the original laboratory or clinical research within the journal’s scope of interests. Method and technology development papers including computational analysis are welcome in this article type. Format guide:
- Title page, Abstract, Keywords, Introduction, Materials and methods, Results,
- Word limit: 5000 words (excluding the abstract, references, figure/tables)
- Statement of Significance: Key points should be summarized on the title page in 50-words or fewer; 3-5 keywords
- References: 50 or fewer
- Abstract: Up to 250 words, structured using the headings Background, Methods, Results, and Conclusions, must be written in English
- Tables/figures/images: 7 or fewer; data in the text should not be repeated extensively in captions/footnotes.
- Publication of longer manuscripts is at the discretion of the editor.
- Statements required with manuscript submission: Funding, conflict-of-interest, ethics and consent, data availability, and animal research
- Authors must fully declare all funding information relevant to the study, including specific grant numbers, under a separate subheading.
Brief Reports:
Convey a focused original research finding. Format guide:
- Title page, Abstract, Keywords, Introduction, Materials and methods, Results, Discussion, Acknowledgements, References, Figure Legends, Tables
- Word limit: 2,000 words (excluding abstract, references, figures/tables)
- Statement of Significance: Key points should be summarized on the title page in 50 words or fewer, 3-5 keywords
- Abstract: Up to 150 words, unstructured, must be written in English
- References: 25 or fewer
- Figures/tables: up to 3
- Statements required with manuscript submission: Funding, conflict-of-interest, ethics and consent, data availability, animal research
- Authors must fully declare all funding information relevant to the study, including specific grant numbers, under a separate subheading.
Reviews:
ABT will publish scholarly, comprehensive reviews that summarize and critically evaluate research in the field, addressing and identifying future implications. They should inform readers of the state-of-the-art of a particular area, provide a critical view, or a historical perspective. Although the focus may be the author's own work, references to the works of others should be included. Review topics should reflect trends and progress or a synthesis of data. Format guide:
- Word limit: 5000 words (excluding the abstract, references, figures/tables)
- Statement of Significance: Key points should be summarized on the title page in 50 words or fewer, 3-5 keywords
- Abstract: Up to 250 words, unstructured; text abstracts must be written in English
- References: 150 or fewer
- Tables/figures/images: 5 or fewer; data in the text should not be repeated extensively in captions/footnotes
- Publication of longer manuscripts is at the discretion of the editors.
- Statements required with manuscript submission: Funding, conflict-of-interest, data availability
- Authors must fully declare all funding information relevant to the study, including specific grant numbers, under a separate subheading.
Mini reviews or perspective articles:
The same topics and formatting as a review, but with a focused message. Format Guide:
- Word limit: 3,000 words
- Statement of Significance: Key points should be summarized on the title page in 50 words or fewer, 3-5 keywords
- Abstract: Up to 150 words, unstructured, must be written in English
- References: 50 or fewer
- Figures/tables: up to 3
- Statements required with manuscript submission: Funding, conflict-of-interest, data availability
- Authors must fully declare all funding information relevant to the study, including specific grant numbers, under a separate subheading.
Meeting Reports:
- Word limit: 3,000 words (excluding the abstract, references, figures/tables)
- Statement of Significance: Key points should be summarized on the title page in 50 words or fewer, 3-5 keywords
- Abstract: Up to 250 words, unstructured, must be written in English
- References: 50 or fewer
- Tables/figures/images: 4 or fewer
- Statements required with manuscript submission: Funding, conflict-of-interest, data availability
- Authors must fully declare all funding information relevant to the study, including specific grant numbers, under a separate subheading.
News and Views:
These papers focus attention on research paper(s) published in Antibody Therapeutics or other major scientific journals. Format guide:
- Word limit: 2,000 words (excluding abstract, references, figures/tables)
- Statement of Significance: Key points should be summarized on the title page in 50-words or fewer, 3-5 keywords
- References: 10 or fewer
- Tables/figures/images: 1
- Statements required with manuscript submission: Funding, conflict-of-interest, data availability
- Authors must fully declare all funding information relevant to the study, including specific grant numbers, under a separate subheading.
Interviews:
These papers focus attention on interviews with experts in the field. Interviews can be structured as Questions and Answers. No abstract is needed. Format guide:
- Word limit: 2,000 words (excluding abstract, references, figures/tables)
- Statement of significance: Key points should be summarized on the title page in 50 words of fewer, 3-5 keywords
- References: 10 or fewer
- Tables/figures/images: 1
- Statements required with manuscript submission: Funding, conflict-of-interest, data availability
- Authors must fully declare all funding information relevant to the study, including specific grant numbers, under a separate subheading.
Editorials:
These papers are normally written by the Editor-in-Chief or an editorial board member invited by the Editor-in-Chief. They normally discuss research paper(s) published in the same issue in the journal or important issues for the journal or the antibody engineering and therapy field. Format guide:
- Title page, Abstract, Keywords, Acknowledgements, References, Figure Legends, Tables
- Word limit: 3,000 words (excluding abstract, references, figures/tables)
- Statement of Significance: Key points should be summarized on the title page in 50 words or fewer, 3-5 keywords
- Abstract: Up to 150 words, unstructured, must be written in English
- References: 50 or fewer
- Figures/tables: up to 3
- Statements required with manuscript submission: Funding, conflict-of-interest, data availability
- Authors must fully declare all funding information relevant to the study, including specific grant numbers, under a separate subheading.
Manuscript Preparation
- On the first page please include the title of paper, all author names, all author affiliations, and the address (including email) of the corresponding author. If there are multiple corresponding authors then nominate one for communication with the editorial office.
- Each author affiliation must be formatted as follows: Department, Institution, City, State, Country." An example is below:
- 2Department of Neurology, Munich University, Munich, Germany;
- 3Department of Radiology, Berlin University, Berlin, Germany;
- 4Department of Health, University of Oxford, Oxford, UK
- Department of Molecular Biology, Princeton University, New Jersey, US
- We suggest a maximum length of 250 words for the Abstract. Avoid reference citations and abbreviations in the Abstract.
- Tables and figures should be accompanied by a legend. Please use a common image format for figures (e.g. pdf, eps, gif, tif, jpg). The initial submission can have figures and text in one file, rather than separate files if desired. You must number all Figures (e.g., Figure 1, Figure 2, Figure 3) and reference them in the text. Further information on figures can be found on the Preparing Your Manuscript webpage.
- Some of our journals publish videos as part of the article and others accept them as supplementary material. A still image of the video will appear in the print version. Instructions as to how to submit correct files (acceptable formats and codecs) can be found on the Video and Media webpage.
- References should be formatted in Oxford SciMed at submission, and authors are responsible for their accuracy. For instructions you can download a pdf document.
- Acknowledgements and details of all funding sources should be included at the end of the text. Please refer to your funding organizations to acknowledge their support. PubMed Central links will require a specific grant number to be referenced.
- Please list all author contributions upon submission of the manuscript.
- Please also define non-standard abbreviations at the first occurrence and number figures and tables consecutively.
Upon revision papers should be submitted in an editable file format (i.e. not PDF) and figures should be submitted as separate, high-resolution, files.
For information on Latex files, please see the Preparing Your Manuscript webpage.
Figures
For information on how to submit figure files, please see the Oxford Journals page on figures.
You can also send queries about figure files to abt.editorialoffice@publishingsolutions.net.
Figure accessibility and alt text
Incorporating alt text (alternative text) when submitting your paper helps to foster inclusivity and accessibility. Good alt text ensures that individuals with visual impairments or those using screen readers can comprehend the content and context of your figures. The aim of alt text is to provide concise and informative descriptions of your figure so that all readers have access to the same level of information and understanding, and that all can engage with and benefit from the visual elements integral to scholarly content. Including alt text demonstrates a commitment to accessibility and enhances the overall impact and reach of your work.
Alt text is applicable to all images, figures, illustrations, and photographs.
Alt text is only accessible via e-reader and so it won’t appear as part of the typeset article.
Detailed guidance on how to draft and submit alt text.
References
These should be cited in the text by sequential number only, in order of appearance, and listed numerically in the References section. The initial version of a paper published online can be cited by the Digital Object Identifier (doi) but, if available, the reference should also include the citation of the final version. Authors should check all references carefully, and in particular ensure that all references in the Reference section are cited in the text. Note that multiple references or page spans under one number are not allowed.
Authors are encouraged to contact the editorial office if they are in any doubt about prior submission.
You can download the current reference style for this journal at EndNote's website under ‘Nucleic Acids Research’
Citations should conform to the following examples. Journal names should be abbreviated in the style of Chemical Abstracts. Where the list of Authors is extensive it is acceptable to list the first 10 Authors followed by et al. Note that full titles of journal articles must be provided.
- Schmitt,E., Panvert,M., Blanquet,S. and Mechulam,Y. (1995) Transition state stabilisation by the 'high' motif of class I aminoacyl-tRNA synthetases: the case of Escherichia coli methionyl-tRNA synthetase. Nucleic Acids Res., 23, 4793-4798.
- Huynh,T.V., Young,R.A. and Davies,R.W. (1988) Constructing and screening cDNA libraries in lambdagt10 and lambdagt11. In Glover,D.M. (ed.), DNA Cloning - A Practical Approach. IRL Press, Oxford, Vol. I, pp. 49-78.
- Maniatis,T., Fritsch,E.F. and Sambrook,J. (1982) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- Burnett,R.C. (1993) EMBL accession no. X52486.
- Capaldi,S., Getts,R.C. and Jayasena,S.D. (2000) Signal amplification through nucleotide extension and excision on a dendritic DNA platform. Nucleic Acids Res., 28, e21.
- Qiao,D., Chen,W., Stratagoules,E. and Martinez,J. (March 10, 2000) Bile acid-induced activation of activator protein-1 requires both extracellular signal-regulated kinase and protein kinase C signaling. J. Biol. Chem., 10.1074/jbc.M908890199
- Qiao,D., Chen,W., Stratagoules,E. and Martinez,J. (2000) Bile acid-induced activation of activator protein-1 requires both extracellular signal-regulated kinase and protein kinase C signaling. J. Biol. Chem., 275, 15090-15098. First published on May 19, 2000, 10.1074/jbc.M908890199
- Bernhagen,J., Elkine,B., Geiger,G., Tovar,G. and Vitzthum,F. (1999) Patent DE-198198889.2-44; PCT/WO/EP/99/03047.
Supplementary data
Submit all material to be considered as Supplementary Material online at the same time as the main manuscript. Ensure that the supplementary material is referred to in the main manuscript at an appropriate point in the text. Supplementary material will be available online only and will not be copyedited, so ensure that it is clearly and succinctly presented, and that the style conforms with the rest of the paper. Also ensure that the presentation will work on any Internet browser. It is not recommended for the files to be more than 2 MB each, although exceptions can be made at the editorial office's discretion.
Pre-submission Language Editing
Language editing to ensure that the academic content of your paper is fully understood by journal editors and reviewers is optional. Language editing does not guarantee that your manuscript will be accepted for publication. For further information on this service, please visit our language services page. Several specialist language editing companies offer similar services and you can also use any of these. Authors are liable for all costs associated with such services. Please note that edited manuscripts will still need to undergo peer-review by the journal.
Proofing
Authors will receive a link to the PDF proof of their manuscript on our online system by email, and it is essential that a current email address is supplied with all manuscripts. Proofing instructions will accompany the PDF file but the proof should be checked immediately upon receipt and uploaded in accordance with covering instructions. Only essential corrections should be made at the proof stage.
Advance Access
Advance Access allows for papers to be published online soon after they have been accepted for publication. Advance Access articles are a mix of accepted manuscripts, labeled as “Accepted Manuscripts,” and finalized manuscripts, labeled as “Corrected Proofs.” Posted Accepted Manuscripts have been accepted by the journal but have not been copyedited or formatted per journal style. Copyediting may lead to minor differences between the Accepted Manuscript and the Corrected Proof; there will be changes to the formatting and there may also be differences in the quality of the graphics. Appearance in Advance Access constitutes official publication, though the articles have not yet been paginated for inclusion in a specific issue of the journal. The Advance Access version can be cited by a unique DOI (Digital Object Identifier). When the Corrected Proof is paginated into an issue, it will then be removed from the Advance Access page.
Contact us
For questions regarding submission and review, including appeals, you can reach the editorial office by email at abt.editorialoffice@publishingsolutions.net
After your paper has been sent to production, you can contact OUP’s Author Support team at jnls.author.support@oup.com for questions regarding the production process or publication. Please see Post-publication changes if you would need to request a substantive change to your published paper.
